🚀 VC round data is live in beta, check it out!
Compass Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Compass Therapeutics and similar public comparables like Geron, Changchun BCHT, UroGen Pharma, Xeris Biopharma and more.
Compass Therapeutics Overview
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Founded
2018
HQ
Employees
35
Website
Sectors
Financials (LTM)
EV
$881M
Compass Therapeutics Financials
Compass Therapeutics reported last 12-month revenue of $392K and negative EBITDA of ($76M).
In the same LTM period, Compass Therapeutics generated $99K in gross profit, ($76M) in EBITDA losses, and had net loss of ($69M).
Revenue (LTM)
Compass Therapeutics P&L
In the most recent fiscal year, Compass Therapeutics reported revenue of — and EBITDA of ($71M).
Compass Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $392K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $99K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($76M) | XXX | ($71M) | XXX | XXX | XXX |
| EBITDA Margin | (19394%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (19144%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($69M) | XXX | ($66M) | XXX | XXX | XXX |
| Net Margin | (17584%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Compass Therapeutics Stock Performance
Compass Therapeutics has current market cap of $1B, and enterprise value of $881M.
Market Cap Evolution
Compass Therapeutics' stock price is $5.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $881M | $1B | 0.0% | XXX | XXX | XXX | $-0.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCompass Therapeutics Valuation Multiples
Compass Therapeutics trades at 2244.7x EV/Revenue multiple, and (11.6x) EV/EBITDA.
EV / Revenue (LTM)
Compass Therapeutics Financial Valuation Multiples
As of April 19, 2026, Compass Therapeutics has market cap of $1B and EV of $881M.
Equity research analysts estimate Compass Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Compass Therapeutics has a P/E ratio of (15.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $881M | XXX | $881M | XXX | XXX | XXX |
| EV/Revenue | 2244.7x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (11.6x) | XXX | (12.3x) | XXX | XXX | XXX |
| EV/EBIT | (11.7x) | XXX | (12.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 8923.1x | XXX | — | XXX | XXX | XXX |
| P/E | (15.7x) | XXX | (16.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (17.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Compass Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Compass Therapeutics Margins & Growth Rates
Compass Therapeutics' revenue in the last 12 month grew by 4193%.
Compass Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Compass Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4193% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (19394%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4642% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14547% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Compass Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Compass Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Geron | XXX | XXX | XXX | XXX | XXX | XXX |
| Changchun BCHT | XXX | XXX | XXX | XXX | XXX | XXX |
| UroGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Xeris Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| uniQure | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Compass Therapeutics M&A Activity
Compass Therapeutics acquired XXX companies to date.
Last acquisition by Compass Therapeutics was on XXXXXXXX, XXXXX. Compass Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Compass Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCompass Therapeutics Investment Activity
Compass Therapeutics invested in XXX companies to date.
Compass Therapeutics made its latest investment on XXXXXXXX, XXXXX. Compass Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Compass Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Compass Therapeutics
| When was Compass Therapeutics founded? | Compass Therapeutics was founded in 2018. |
| Where is Compass Therapeutics headquartered? | Compass Therapeutics is headquartered in United States. |
| How many employees does Compass Therapeutics have? | As of today, Compass Therapeutics has over 35 employees. |
| Who is the CEO of Compass Therapeutics? | Compass Therapeutics' CEO is Thomas J. Schuetz. |
| Is Compass Therapeutics publicly listed? | Yes, Compass Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Compass Therapeutics? | Compass Therapeutics trades under CMPX ticker. |
| When did Compass Therapeutics go public? | Compass Therapeutics went public in 2020. |
| Who are competitors of Compass Therapeutics? | Compass Therapeutics main competitors are Geron, Changchun BCHT, UroGen Pharma, Xeris Biopharma. |
| What is the current market cap of Compass Therapeutics? | Compass Therapeutics' current market cap is $1B. |
| What is the current revenue of Compass Therapeutics? | Compass Therapeutics' last 12 months revenue is $392K. |
| What is the current revenue growth of Compass Therapeutics? | Compass Therapeutics revenue growth (NTM/LTM) is 4193%. |
| What is the current EV/Revenue multiple of Compass Therapeutics? | Current revenue multiple of Compass Therapeutics is 2244.7x. |
| Is Compass Therapeutics profitable? | No, Compass Therapeutics is not profitable. |
| What is the current EBITDA of Compass Therapeutics? | Compass Therapeutics has negative EBITDA and is not profitable. |
| What is Compass Therapeutics' EBITDA margin? | Compass Therapeutics' last 12 months EBITDA margin is (19394%). |
| What is the current EV/EBITDA multiple of Compass Therapeutics? | Current EBITDA multiple of Compass Therapeutics is (11.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.